This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taylor, D. D. Articles by Whiteside, T. L. Search for Related Content PubMed PubMed Citation Articles by Taylor, D. D. Articles by Whiteside, T. L.

T-Cell Apoptosis and Suppression of T-Cell Receptor/CD3- by Fas Ligand-Containing Membrane Vesicles Shed from Ovarian Tumors

Departments of Obstetrics & Gynecology and Radiation Oncology, University of Louisville School of Medicine, Louisville, Kentucky [D. D. T., Ç. G-T., K. S. L.], and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania [J. S., T. L. W.]

ABSTRACT

Purpose: The accumulation of shed plasma membrane vesicles in the peripheral circulation is unique to cancer. Because these membrane fragments (MFs) express biologically active components, such as Fas ligand (FasL), the objective of this study was to define the link between the presence of shed membrane vesicles, apoptosis, and suppression of T-cell receptor/CD3- expression in T lymphocytes of patients with ovarian cancer.

Experimental Design: MF shedding was measured chromatographically in sera from women with ovarian cancer (n = 11) and, as controls, non-cancer-bearing females (n = 9) and women with benign ovarian disease (n = 4). FasL associated with these shed fragments was assayed by Western immunoblots, whereas HLA class I expression was defined by slot-blotting. The effect of shed MFs on CD3- expression was evaluated using a T-cell bioassay, and apoptosis of circulating T cells was measured by a cell-death ELISA and electrophoretic analysis of caspase-3.

Results: MFs were undetectable in control sera, and their levels were significantly elevated in sera from women with ovarian cancer. These tumor-derived MFs expressed 41-kDa FasL and HLA class I antigens. In co-incubation experiments, dose-dependent suppression of T-cell receptor/CD3- expression by MFs was observed. Decreases in expression correlated with the level of FasL in MFs but not with the level of HLA. The suppression of CD3- by MFs appeared to be linked to the induction of apoptosis and caspase-3 within T cells.

Conclusion: Our results suggest that FasL associated with tumor-derived MFs is responsible for apoptosis of T lymphocytes and a concomitant loss of -chain expression in patients with ovarian carcinoma.

This article has been cited by other articles:

				R. Valenti, V. Huber, M. Iero, P. Filipazzi, G. Parmiani, and L. Rivoltini Tumor-Released Microvesicles as Vehicles of Immunosuppression Cancer Res., April 1, 2007; 67(7): 2912 - 2915. [Abstract] [Full Text] [PDF]

				A. E. Albers, C. Visus, T. Tsukishiro, R. L. Ferris, W. Gooding, T. L. Whiteside, and A. B. De Leo Alterations in the T-Cell Receptor Variable {beta} Gene-Restricted Profile of CD8+ T Lymphocytes in the Peripheral Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., April 15, 2006; 12(8): 2394 - 2403. [Abstract] [Full Text] [PDF]

				O. Bohana-Kashtan and C. I. Civin Profiling Tumor Counterattack: Do Fas Ligand-Containing Microvesicles Reduce Anticancer Immunity? Clin. Cancer Res., February 1, 2005; 11(3): 968 - 970. [Full Text] [PDF]

				J. W. Kim, E. Wieckowski, D. D. Taylor, T. E. Reichert, S. Watkins, and T. L. Whiteside Fas Ligand-Positive Membranous Vesicles Isolated from Sera of Patients with Oral Cancer Induce Apoptosis of Activated T Lymphocytes Clin. Cancer Res., February 1, 2005; 11(3): 1010 - 1020. [Abstract] [Full Text] [PDF]

				L. E. Graves, E. V. Ariztia, J. R. Navari, H. J. Matzel, M. S. Stack, and D. A. Fishman Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles Cancer Res., October 1, 2004; 64(19): 7045 - 7049. [Abstract] [Full Text] [PDF]